SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Anti-liver-kidney microsome type 1 (LKM1) autoantibodies directed against the cytochrome P450 2D6 (CYP2D6) are considered specific markers of type 2 autoimmune hepatitis, but are also found in 5% of sera from patients chronically infected by hepatitis C virus (HCV). Molecular mimicry between HCV proteins and CYP2D6 has been proposed to explain the emergence of these autoantibodies. Anti-LKM1 autoantibodies from hepatitis C–infected patients were affinity-purified against immobilized CYP2D6 protein and used to screen a phage display library. CYP2D6 conformational epitopes were identified using phage display analysis and the identification of statistically significant pairs (SSPs). Cross-reactivity between CYP2D6 and HCV protein candidates was tested by immunoprecipitation. Nineteen different clones were isolated, and their sequencing resulted in the mapping of a conformational epitope to the region of amino acids 254-288 of CYP2D6. Candidate HCV proteins for molecular mimicry included: core, E2, NS3 and NS5a. Affinity-purified autoantibodies from HCV+/LKM1+ patients immunoprecipitated either NS3, NS5a, or both, and these reactivities were specifically inhibited by immobilized CYP2D6. In conclusion, HCV+/LKM1+ sera recognize a specific conformational epitope on CYP2D6 between amino acids 254 to 288, the region that contains the major linear epitope in type 2 autoimmune hepatitis patients. Cross-reactivity due to molecular mimicry at the B-cell level was shown between the CYP2D6 and the HCV NS3 and NS5a proteins and could explain the presence of anti-LKM1 in patients chronically infected with HCV. Further investigation of the role played by this molecular mimicry in HCV-infected patients may lead to more specific strategies for diagnosis and treatment. (HEPATOLOGY 2005.)

The number of people infected by hepatitis C virus (HCV) worldwide is estimated at 170 million, with a global prevalence of 3%.1, 2 Several autoimmune phenomena have been reported to be frequently associated with chronic HCV infection, namely, rheumatoid symptoms, keratoconjunctivitis sicca, lichen planus, glomerulonephritis, mixed cryoglobulinemia, and circulating autoantibodies.3–7 When serious liver injury occurs in chronic hepatitis C infection, an autoimmune mechanism may contribute to hepatic destruction.8

The presence of Liver Kidney Microsomes type 1 (LKM1) autoantibodies in chronic HCV-infected patients is puzzling. Although anti-LKM1 autoantibodies are considered to be a specific serological marker of type 2 autoimmune hepatitis (AIH-2), 5% to 10% of patients with chronic HCV hepatitis are also LKM1 positive.9–11 LKM1 autoantibodies are known to be specifically directed against cytochrome P450IID6 (CYP2D6),12, 13 a protein located on the cytoplasmic side of the endoplasmic reticulum of hepatocytes. Circulating autoantibodies in sera from patients with AIH-2 recognize linear epitopes on the CYP2D6 protein, whereas most HCV+/LKM1+ sera (70%) are only directed against conformational epitopes of this autoantigen.14, 15 Recently, a new method that combines phage display analysis and a bioinformatics analysis to identify statistically significant pairs (SSPs)16 has eased the study and identification of conformational epitopes. This method has been used to precisely map a B-cell conformational epitope in human immunodeficiency virus (HIV)16 and has opened the way to properly study these discontinuous epitopes, which composed the vast majority of recognized sequences.17

The origin of LKM1 autoantibodies in both HCV infection and AIH is unknown. Their presence cannot be solely attributed to the release of sequestered hepatocyte proteins, because anti-LKM1 autoantibodies are completely absent in sera from patients with other liver diseases.18 Specific major histocompatibility complex loci have been described in association with the presence of LKM1 autoantibodies in both AIH-2 patients19 and HCV chronically infected patients.20 Molecular mimicry between HCV proteins and CYP2D6 could explain the emergence of these autoantibodies. The hepatitis C virus is made of single-stranded RNA that is translated into one polyprotein that is cleaved by cellular and viral proteases into 10 structural (core, E1, E2) and nonstructural (P7, NS2, NS3, NS4a, NS4b, NS5a, NS5b) proteins.21 The aim of our study was to characterize the reactivity of LKM1+ autoantibodies in HCV chronically infected patients and test for possible molecular mimicry between HCV proteins and CYP2D6, in the hope of shedding light on an otherwise poorly understood process by which LKM1 autoantibodies are produced in both HCV-infected and autoimmune hepatitis patients.

Materials and Methods

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Patient's Sera.

Sera were obtained from patients (2 females and 1 male, average age: 63 ± 12 years) chronically infected by HCV 1a who were shown to be LKM1+ by indirect immunofluorescence using rat or human liver and kidney sections and by western blot against human liver microsomal fractions as described.18, 22 HCV infection was diagnosed by second-generation recombinant immunoblot assay or polymerase chain reaction. Sera from patients with type 2 autoimmune hepatitis (LKM1+), but not infected by HCV, and pooled sera from healthy individuals (LKM1−) and HCV-infected (LKM1−) patients were used as control. This study conforms to current ethical guidelines and was approved by the local ethical committee.

Human CYP2D6 and HCV Constructions.

The complete CYP2D6 cDNA (GenBank accession number: AF009606), obtained from Dr U. Meyer (Basel, Switzerland), was sub-cloned into pGem3 (Pharmacia Biotech, Uppsala, Sweden) and pMalcrI (New England Biolabs, Beverly, MA) vectors at their EcoRI sites. The HCV polyprotein cDNA (provided by Dr D. Moradpour, Freiburg, Germany) was used to amplify the different specific proteins (E2, Core, NS3, and NS5a). The polymerase chain reaction product of each HCV protein was cloned into the pCRII-TOPO TA cloning vector (Invitrogen, Carlsbad, CA) and used to chemically transfect TOP10 competent cells (Invitrogen).

Affinity Purification of LKM1+/HCV+ Sera.

The MBP/CYP2D6 fusion product was produced in vitro (pMAL Protein Fusion and Purification System; New England Biolabs). The protein obtained was coupled to a resin (NHS-activated Sepharose 4 Fast Flow; Amersham Life Sciences, Oakville, Canada) and free sites properly blocked by an ethanolamine solution. HCV+/LKM1+ patients' sera were diluted 1:10 in PBS (1 mL final volume) then loaded 3 times on 120 μL of the prepared affinity column. The column was then washed and the autoantibodies eluted with an acid solution (glycine-HCl, pH 2.5), washed, and eluted again with a basic solution (Triethylamine pH 11.5). The eluted fractions were concentrated to 900 μL by centrifugation in a Microcon YM-30 filter column (Millipore, Billerica, MA).

Western Blot Analysis.

Proteins of the human liver microsomal fraction22 were separated by electrophoresis on a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto nitrocellulose filters (Amersham). The membrane was blocked with 5% powder milk in TBST (10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 0.05% Tween 20). The nitrocellulose filters were then incubated for 2 hours at room temperature with the purified HCV+/LKM1+ sera and control sera in TBST/1% powder milk. The secondary antibody used was conjugated to peroxidase (Biosource International, Camarillo, CA), diluted to 1:10,000 in TBST/1% powder milk. Bound peroxidase was detected with chemiluminescence blotting substrate (Boehringer Mannheim, Germany), according to the manufacturer's instructions.

Immunoprecipitation of In Vitro Translated Proteins From CYP2D6 and HCV DNA Constructions.

The proteins coded by the TOPO vectors were individually synthesized in vitro (TnT Coupled Reticulocyte Systems; Promega, Madison, WI) and labeled with 35S-methionine (Amersham Life Sciences). Sera (5 μL) were individually incubated with 50,000 cpm of these marked proteins, 2 mg protein A-Sepharose (Sigma-Aldrich Canada, Oakville, Canada) and 500 μL of a proper incubating buffer with agitation for 2 hours at 4°C.23 The protein A-associated immunoglobulins were washed 6 times.23 The remaining pellet was then denatured in a loading buffer followed by 5 minutes' boiling before loading on the denaturing SDS-PAGE. After electrophoresis, the gel was fixed, Coomassie colored, washed, and dried before being exposed overnight against an autoradiography film (BiomaxMR; Kodak, Rochester, NY).

Mimotope Identification Through Phage Display.

The purified and concentrated autoantibodies were used as the selecting matrix with a phage display library (Ph.D.-7 Phage Display Peptide Library Kit; New England Biolabs) with 150 μL for every selection cycle. The retained phages, eluted with CYP2D6 fusion protein (20 μg) and purified, were then sequenced (Sequenase Version 2.0 DNA Sequencing Kit, USB, Cleveland, OH). Nineteen different phages selected by the 3 purified sera after the third cycle were pooled at equal titers and used as the peptide bank for a fourth cycle with each of the purified sera at two temperature conditions, 4°C and room temperature (20°C). The phages from this cycle were also purified and sequenced. The sequences obtained were then compared between themselves and to the CYP2D6 (GeneBank acc.num.: P10635) and HCV-1a (GeneBank acc. num.:AAA45676) sequences using the Vector NTI program (InforMax, Carlsbad, CA).

CYP2D6 Conformational Epitope Analysis.

The 19 mimotopes obtained by phage display were used to find SSPs for the identification of conformational epitopes on the CYP2D6 protein. According to the process described by Enshell-Seijffers et al.,16 mimotope sequences were simplified by using a degenerate amino acid code that groups amino acids with similar antibody-binding characteristics (R,K = B; E,D = J;S,T-O; L,V,I = U;Q,N = X; W,F = Z). The amino acid pairs were then ranked by their occurrence in the different mimotopes. The theoretical occurrences (based on randomness) of the different pairs was then calculated, and the over-represented amino acid pairs were identified as SSPs. The crystallographic model of the CYP2D624 (provided by Dr Lewis, University of Surrey, UK) was used to search for tandem and bridged SSPs on the protein surface. Amino acids of a pair had to be within 8Å of each other. The SSPs then formed clusters on the surface of the protein (a cluster is defined as a pair that is within 8Å of a pair which is within 8Å of a second pair, etc.). The region that contains a cluster of SSPs on the surface of a protein was considered a putative epitope.

Immunoabsorption of Purified HCV+/LKM1+ Sera.

To confirm the results obtained by immunoprecipitation, 50 μL purified HCV+/LKM1+ sera was adsorbed on either 100 μL control resin (GST-Sepharose) or 100 μL CYP2D6-sepharose. The unabsorbed sera were then used to immunoprecipitate (as described above) CYP2D6 (control), NS3, or NS5a proteins.

Protein Structural Analysis.

The protein structure was analyzed with the Swiss PDB Viewer 3.7 program,25 and the final images were rendered with POVRAY version 3.5.

Results

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Analysis of HCV+/LKM1+ Patients Sera Purification.

The sera of the 3 HCV+ patients had been previously identified as LKM1+ by immunofluorescence and western blot. These results were confirmed by immunoprecipitation with radiolabeled CYP2D6, thereby indicating that these sera recognize both native and denatured CYP2D6. The different fractions obtained after the affinity purification of anti-LKM1 autoantibodies using a CYP2D6-sepharose column are shown in Fig. 1. Affinity-purified LKM1 antibodies were mainly reactive against the native form of CYP2D6 by immunoprecipitation compared with western blot (Fig. 1A-B), thereby suggesting that the purification against native CYP2D6 led to the selection of antibodies recognizing conformational epitopes of the molecule. The antibodies directed against linear epitopes were lost during the purification, possibly because linear epitopes can be hidden in a correctly folded CYP2D6 protein. The purified autoantibodies were of the immunoglobulin G isotype (data not shown).

thumbnail image

Figure 1. HCV+/LKM1+ sera purification. (A) Western blot analysis of purified HCV+/LKM1+ patient's sera. Thirty micrograms microsomal fractions were used as substrate for antibodies testing from various purification steps. (a) Negative control (HCV+/LKM1− serum). (b) Patient's serum (HCV+/LKM1+). (c) Patient's serum (unretained fraction). (d) Purified serum (acid elution). (e) Purified serum (basic elution). (f) Concentrated purified anti-CYP2D6 antibodies. (B) Immunoprecipitation with purified HCV+/LKM1+ patients' sera. Radiolabeled CYP2D6 was immunoprecipitated with either (P) purified anti-CYP2D6 antibodies from HCV+/LKM1+ or (N) Negative control (HCV+/LKM1− serum).

Download figure to PowerPoint

Identification of a Possible Molecular Mimicry Between Mimotopes and HCV Proteins.

Nineteen mimotopes were identified using the purified LKM1+ sera and the phage display technique. Based on the presumption that a conformational epitope could have a partial homology with the antigen amino acids sequence, the mimotope sequences were compared with HCV protein sequences (Fig. 2). Four proteins (core, E2, NS3, and NS5a) were found as having homologies with several mimotopes.

thumbnail image

Figure 2. Linear alignment of identified mimotopes with HCV 1a polyprotein amino acid sequence. Phage sequences obtained after phage display with the 3 purified patient's sera were aligned against the HCV 1a polyprotein to identify candidates for a molecular mimicry; significant alignments are shown.

Download figure to PowerPoint

Identification of LKM1 Conformational Epitopes on the CYP2D6.

The phage display technique allows the detection of both linear and conformational epitopes.26, 27 The mimotope sequences were analyzed using a novel approach16 that aims at mapping conformational epitopes through the identification of SSPs of amino acids. Using this approach, 3 SSPs were identified (Fig. 3): OO, OU, JO. These sequences use a degenerate code that groups amino acids with similar side chains according to their antibody-binding characteristics (Fig. 3B). The amino acid pairs were ranked by their occurrence in the different mimotopes (Fig. 3C) and compared with their theoretical occurrences (based on randomness) (Fig. 3D). The over-represented pairs were identified as statistically significant pairs (SSPs). These 3 SSPs were then mapped on the CYP2D6 crystallographic model as tandem and bridged amino acids (within 8 Å of each other). These identified pairs (OO, OU, JO) formed a unique cluster in the region of amino acids 254 to 288 (Fig. 4A). This cluster is the only one that encompasses all 3 amino acids pairs within 8 Å of one another. These amino acids are on the surface of the protein and span a region of 13 Å by 28 Å (364 Å2) (Fig. 4B). The region of amino acids 254 to 288 is contained within a homogenous region of negative electrostatic potential (Fig. 4C). These facts indicate that the region of amino acids 254 to 288 of the CYP2D6 contains a putative conformational epitope mimicked by the mimotopes identified with the affinity-purified HCV+/LKM1+ sera.

thumbnail image

Figure 3. Identification of statistically significant pairs (SSPs). (A) Mimotope sequences obtained from each patient by phage display analysis. (B) Amino acid pair sequences derived from the mimotope sequences using a degenerate code that groups amino acids with similar antibody-binding characteristics. (C) Occurrence of amino acids pairs. (D) Identification of statistically significant pairs (SSPs) by comparison between the experimental occurrence of frequent amino acid pairs and their theoretically predicted occurrence.

Download figure to PowerPoint

thumbnail image

Figure 4. CYP2D6 conformational epitope analysis. (A) Identification of clusters of pairs on CYP2D6 structure. Pairs (OU, OO, JO) are colored, (GLU = green; SER = red; LEU = yellow; THR = pink); only the region of amino acids 254-288 contains all 3 SSPs (boxed). (B) Amino acids 254-288 are accessible on the surface of CYP2D6 and within an area of 364Å2. Significant amino acids of the 254-288 amino acids region are colored. (C) Electrostatic potential. Amino acids 254-288 of CYP2D6 are contained within a homogenous region of negative electrostatic potential.

Download figure to PowerPoint

Molecular Mimicry and Cross-reactivity Between HCV Proteins and CYP2D6.

The mimotopes isolated with the affinity-purified HCV+/LKM1+ sera showed sequence homologies with 4 HCV proteins (core, E2, NS3, and NS5a). These homologies were used as a starting point to look for possible molecular mimicry and cross-reactivity between HCV proteins and the CYP2D6. The four candidate proteins were synthesized in vitro and used in an immunoprecipitation assay. The HCV+/LKM1+ sera purified against the CYP2D6-sepharose (P1, P2 and P3) were used to immunoprecipitate the four previously identified HCV proteins (Fig. 5A-B). If these sera purified for CYP2D6 binding antibodies could immunoprecipitate an HCV protein, this would indicate that the same antibody, present in HCV+/LKM1+ sera, binds to both CYP2D6 and to an HCV protein. As is shown in Fig. 5A-B, the purified sera from patient 1 immunoprecipitated the NS3 protein, patient 2 immunoprecipitated NS5a, and patient 3 immunoprecipitated both NS3 and NS5a. Sera from type 2 AIH patients with LKM1 autoantibodies did not immunoprecipitate either NS3 or NS5a (data not shown). This indicates that a molecular mimicry and cross-reactivity at the B cell level exists between the CYP2D6 and the NS3 and NS5a proteins from HCV. To confirm that these HCV proteins (NS3 and NS5a) were, in fact, immunoprecipitated by the same antibody, sera were pre-absorbed on either a control resin (GST-Sepharose) or the CYP2D6-sepharose. The pre-absorption with the GST-Sepharose had no effect on the immunoprecipitation of the CYP2D6 or the NS3 and NS5a proteins, whereas the pre-absorption with CYP2D6 removed the antibodies necessary to immunoprecipitate CYP2D6, NS3, or NS5a (Fig. 5C). Altogether, these results confirm that there is in fact molecular mimicry between CYP2D6 and NS3 or NS5a and that cross-reactivity between antibodies recognizing conformational epitopes on these molecules exists.

thumbnail image

Figure 5. Molecular mimicry between CYP2D6, NS3, and NS5a. (A-B) Identification of molecular mimicry. Radiolabeled CYP2D6, core, E2, NS5a, and NS3 were immunoprecipitated with either P1, P2, or P3 HCV+/LKM1+ (patient's sera) purified anti-CYP2D6 antibodies. (N) Negative control (HCV+/LKM1- serum). (C) Confirmation of CYP2D6 cross-reactivity with NS3 and NS5a. Radiolabeled CYP2D6, NS5a, NS3 were immunoprecipitated with 1 of the following: GST-P1, P1 purified serum adsorbed with GST-resin; CYP2D6-P1, P1 purified serum adsorbed with CYP2D6-resin; GST-P2, P2 purified serum adsorbed with GST-resin; CYP2D6-P2, P2 purified serum adsorbed with CYP2D6-resin.

Download figure to PowerPoint

Discussion

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Anti-LKM1 antibodies were first described in patients with chronic active hepatitis.28 The advent of tests for the diagnosis of HCV infection showed that some LKM1(+) chronic active hepatitis patients were infected.29 Later, several studies confirmed that LKM1 autoantibodies are confined to AIH- and HCV-infected patients.18, 30 However, the factors triggering and maintaining this particular and specific B-cell autoimmune response are unknown. A molecular mimicry between HCV antigens and CYP2D6 (the autoantigen recognized by anti-LKM1 antibodies) has been frequently stated as a possible mechanism.31, 32 Here we report, through experimental data, that a molecular mimicry exists between HCV proteins and CYP2D6. This cross-reactivity could explain the presence of anti-LKM1 antibodies in HCV-infected patients.

LKM1 autoantibodies present in chronically infected HCV patients are mainly (70%) directed against the native form of CYP2D6.14, 15 Efforts have been made to identify CYP2D6 epitopes recognized by HCV-infected patients, both linear33 and conformational.34 The study by Sugimura et al.34 identified a conformational epitope (aa 321-379 of CYP2D6) recognized by type 2 AIH and HCV-infected patients through western blot analysis. The possibility that this epitope could also be a discontinuous linear epitope cannot be excluded because these type of autoepitopes have been previously described in type 2 AIH patients.35 The identification of conformational epitopes is a difficult endeavor. This is largely because of the difficulty of producing peptides that adopt their native structure, as found in the native protein. A new method has been recently developed that enables the identification of conformational epitopes through the combined use of phage display analysis36 and the identification of SSPs.16 To ensure that the identified mimotopes were CYP2D6-specific epitopes, the HCV+/LKM1+ sera were affinity-purified against a CYP2D6-sepharose. The purified antibodies were reactive only against the native CYP2D6, indicating that, using this method, only antibodies against conformational epitopes were purified.

Even though a limited number of patients were used, the use of affinity-purified sera and the combined approach of phage display analysis and SSP identification allowed the mapping of a conformational epitope in the region of aa 254-288 of CYP2D6. This epitope comprises an area of 364 Å2 and is within a homogenous field of negative electrostatic potential; these characteristics are consistent with those of a conformational epitope. This region of CYP2D6 also contains the major epitope recognized by sera from patients with AIH-2, the aa 257-269.35 This area of high antigenicity35 of the CYP2D6 seems to elicit distinct immune reactivities in HCV and AIH patients; type 2 AIH patients appear to develop autoantibodies against a linear epitope whereas the HCV patients will do the same against a conformational epitope. This infers that different immune processes are at work (different antigen presentation by antigen-presenting cells, activation of different autoreactive clones) and that these mechanisms are independent of CYP2D6 antigenic properties.

The sequences obtained through phage display were used to identify candidates for a molecular mimicry between an HCV protein and the CYP2D6. Four HCV proteins have been identified as candidates; core, E2, NS3, and NS5a. By immunoprecipitation with purified sera, and the subsequent confirmation by absorption with a CYP2D6 adsorbing resin, molecular mimicry at the B-cell level between the CYP2D6 and NS3 and NS5a was revealed. These results indicate that the same conformational antibodies that recognize CYP2D6 also recognize NS3, NS3, and NS5a or NS5a only. This description of a conformational molecular mimicry between HCV proteins and the CYP2D6 could explain the presence of LKM1 autoantibodies in patients chronically infected with HCV. The putative regions of NS3 and NS5a that cross-react with CYP2D6 (Fig. 2) are highly conserved in HCV genotypes 1a, 1b, 2, 3, 4, 5, and 6 (data not shown).

To further define the molecular mimicry between CYP2D6 and the HCV proteins (NS3, NS5a), the next logical step would be the structural analysis of these molecules and identification of similar structural motifs. Human cytochrome P450 2D6 has not been crystallized, so only a model of its structure based on a mammalian cytochrome has been produced.24 The crystallographic structure of the NS5a protein has not been elucidated yet, except for 30 amino acids of the membrane anchor domain.37 The tertiary structure of the NS3 protease/helicase has been published.38 The analysis of common structural motifs between these 3 proteins is, therefore, very difficult. Using available methods of structure comparison (VAST algorithm,39 Combinatorial Extension method,40 linear sequence alignments [PAM 10] followed by structural superimpositions, etc.), no common structural domain between the modeled CYP2D6 and the NS3 or with the membrane anchor domain of NS5a were found. The crystallography of NS5a and CYP2D6 should enable a more thorough investigation of common structural motifs between these proteins and enable a better representation of the molecular mimicry identified in this study.

The clinical relevance of these findings cannot be understated. Given the conformational nature of these LKM1 epitopes in HCV-infected patients, testing lacks specificity. Identification of the major structural epitopes recognized by LKM1+ sera could lead to new diagnostic tools using arrays of peptide mimics in ELISA settings that would enable simpler, wider testing of HCV+ patients for LKM1 autoantibodies directed against conformational CYP2D6 epitopes. Currently, to develop a diagnostic test for recognition of conformational epitopes, two steps must be achieved: (1) the identification of a specific epitope, and (2) the development of conformational peptide mimicking complex structural conformations. The development of such peptides relies on elaborate computational processes, a science still in its infancy.41, 42 Testing larger numbers of HCV-infected patients for autoantibodies against the aa 254-288 conformational epitope of CYP2D6 would prove interesting, because their prevalence is unknown, and it could help define their clinical relevance. Both pediatric and adult patients infected with HCV and who have LKM1 autoantibodies have been described as having alanine aminotransferase (ALT) flare ups under treatment, which reportedly resolve on discontinuation of interferon treatment.43–47 This reaction could result from an underlying autoimmune process directed against hepatocytes in LKM1+ patients. Patients that are chronically infected with HCV and have LKM1+ autoantibodies therefore should be carefully monitored during treatment with interferon.

In conclusion, antibodies directed against the CYP2D6 present in HCV+/LKM1+ patient's sera can cross-react with HCV proteins (NS3, NS5a). This cross-reactivity could be the result of molecular mimicry at the B cell level, which through an initial reactivity against viral proteins would lead to reactivity against a self-protein. This specific cross-reactivity with HCV protein is compatible with the observation that only patients infected with HCV develop LKM1 autoantibodies. It implies that it is an HCV-specific effect and explains why a molecular mimicry with HCV proteins has been frequently proposed.48, 49 The conformational epitope targeted by the autoantibodies present in HCV+/LKM1+ patient's sera (aa 254-288) is located in the same region as the major linear epitope recognized by type 2 AIH patients. Further identification of the region targeted by LKM1 antibodies in HCV+ patients and elucidation of the mechanism involved in their production will further our understanding of the autoimmune phenomenon present in these patients. Ultimately, these studies may lead to new and more specific strategies for diagnosis and treatment.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

The authors thank Professor Claude C. Roy, MD, for critical reading. Dr. Hugo Soudeyns is a Junior-II Scientist of le Fonds de la Recherche en Santé du Québec.

References

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  • 1
    Bandy U. Hepatitis C virus (HCV): a silent epidemic. Med Health R I 1999; 82: 223224.
  • 2
    Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. HEPATOLOGY 2004; 39: 476483.
  • 3
    Fusconi M, Lenzi M, Ballardini G, Miniero R, Cassani F, Zauli D, et al. Anti-HCV testing in autoimmune hepatitis and primary biliary cirrhosis. Lancet 1990; 336: 823.
  • 4
    Quaranta JF, Tran A, Regnier D, Letestu R, Beusnel C, Fuzibet JG, et al. High prevalence of antibodies to hepatitis C virus (HCV) in patients with anti-thyroid autoantibodies. J Hepatol 1993; 18: 136138.
  • 5
    Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465470.
  • 6
    Divano MC, Parodi A, Rebora A. Anti-GOR antibodies in lichen planus. Dermatology 1994; 188: 205206.
  • 7
    Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003; 325: 135148.
  • 8
    Seelig R, Renz M, Bunger G, Schroter H, Seelig HP. Anti-LKM-1 antibodies determined by use of recombinant P450 2D6 in ELISA and western blot and their association with anti-HCV and HCV-RNA. Clin Exp Immunol 1993; 92: 373380.
  • 9
    Obermayer-Straub P, Manns MP. Hepatitis C and D, retroviruses and autoimmune manifestations. J Autoimmun 2001; 16: 275285.
  • 10
    Muratori P, Muratori L, Verucchi G, Attard L, Bianchi FB, Lenzi M. Non-organ-specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment. Clin Infect Dis 2003; 37: 13201326.
  • 11
    Muratori P, Muratori L, Guidi M, Granito A, Susca M, Lenzi M, et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005; 40: 501507.
  • 12
    Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989; 83: 10661072.
  • 13
    Gueguen M, Yamamoto AM, Bernard O, Alvarez F. Anti-liver-kidney microsome antibody type 1 recognizes human cytochrome P450 db1. Biochem Biophys Res Commun 1989; 159: 542547.
  • 14
    Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993; 104: 17621767.
  • 15
    Parez N, Herzog D, Jacqz-Aigrain E, Homberg JC, Alvarez F. Study of the B cell response to cytochrome P450IID6 in sera from chronic hepatitis C patients. Clin Exp Immunol 1996; 106: 336343.
  • 16
    Enshell-Seijffers D, Denisov D, Groisman B, Smelyanski L, Meyuhas R, Gross G, et al. The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J Mol Biol 2003; 334: 87101.
  • 17
    Barlow DJ, Edwards MS, Thornton JM. Continuous and discontinuous protein antigenic determinants. Nature 1986; 322: 747748.
  • 18
    Vitozzi S, Lapierre P, Djilali-Saiah I, Alvarez F. Autoantibody detection in type 2 autoimmune hepatitis using a chimera recombinant protein. J Immunol Methods 2002; 262: 103110.
  • 19
    Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002; 47: 21392150.
  • 20
    Bogdanos DP, Lenzi M, Okamoto M, Rigopoulou EI, Muratori P, Ma Y, et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 2004; 17: 8392.
  • 21
    Purcell RH. Hepatitis C (Flaviviridae). In: Encyclopedia of Virology. 2nd ed. New York: Webster AGeRG, 1999: 657663.
  • 22
    Amar-Costesec A, Beaufay H, Wibo M, Thines-Sempoux D, Feytmans E, Robbi M, et al. Analytical study of microsomes and isolated subcellular membranes from rat liver. II. Preparation and composition of the microsomal fraction. J Cell Biol 1974; 61: 201212.
  • 23
    Spector DL, Goldman RD, Leinwand LA. Cells: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1998: 72.172.74.
  • 24
    Lewis DF. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 2002; 32: 305323.
  • 25
    Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18: 27142723.
  • 26
    Beland K, Lapierre P, Marceau G, Alvarez F. Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection. J Autoimmun 2004; 22: 159166.
  • 27
    Rowley MJ, Scealy M, Whisstock JC, Jois JA, Wijeyewickrema LC, Mackay IR. Prediction of the immunodominant epitope of the pyruvate dehydrogenase complex E2 in primary biliary cirrhosis using phage display. J Immunol 2000; 164: 34133419.
  • 28
    Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973; 15: 331344.
  • 29
    Lenzi M, Ballardini G, Fusconi M, Cassani F, Selleri L, Volta U, et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 1990; 335: 258259.
  • 30
    Czaja AJ, Taswell HF, Rakela J, Schimek CM. Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. Mayo Clin Proc 1991; 66: 572582.
  • 31
    Lapierre P, Herzog D, Alvarez F. Autoepitopes in Hepatitis C. In: RizzettoM, ed. Proceedings of the IX triennial International Symposium on Viral Hepatitis and Liver disease: Edizioni Minerva Medica, 1997: 460462.
  • 32
    Kerkar N, Ma Y, Hussain M, Muratori L, Targett C, Williams R, et al. A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1. J Immunol Methods 1999; 223: 227235.
  • 33
    Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003; 170: 14811489.
  • 34
    Sugimura T, Obermayer-Straub P, Kayser A, Braun S, Loges S, Alex B, et al. A major CYP2D6 autoepitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens. Autoimmunity 2002; 35: 501513.
  • 35
    Yamamoto AM, Cresteil D, Boniface O, Clerc FF, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993; 23: 11051111.
  • 36
    Parmley SF, Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988; 73: 305318.
  • 37
    Penin F, Brass V, Appel N, Ramboarina S, Montserret R, Ficheux D, et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 2004; 279: 4083540843.
  • 38
    Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure Fold Des 1999; 7: 13531363.
  • 39
    Gibrat JF, Madej T, Bryant SH. Surprising similarities in structure comparison. Curr Opin Struct Biol 1996; 6: 377385.
  • 40
    Shindyalov IN, Bourne PE. Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng 1998; 11: 739747.
  • 41
    Kishore R. Beta-Ala containing peptides: potentials in design and construction of bioactive peptides and protein secondary structure mimics. Curr Protein Pept Sci 2004; 5: 435455.
  • 42
    Honda S, Yamasaki K, Sawada Y, Morii H. 10 residue folded peptide designed by segment statistics. Structure (Camb) 2004; 12: 15071518.
  • 43
    Bortolotti F, Vajro P, Balli F, Giacchino R, Crivellaro C, Barbera C, et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25: 614620.
  • 44
    Gregorio GV, Pensati P, Iorio R, Vegnente A, Mieli-Vergani G, Vergani D. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998; 112: 471476.
  • 45
    Bortolotti F, Muratori L, Jara P, Hierro L, Verucchi G, Giacchino R, et al. Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. J Pediatr 2003; 142: 185190.
  • 46
    Muratori L, Lenzi M, Cataleta M, Giostra F, Cassani F, Ballardini G, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21: 199203.
  • 47
    Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. HEPATOLOGY 1995; 22: 13741378.
  • 48
    Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 13701378.
  • 49
    Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001; 21: 225232.